Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002

Date: 11/11/2025

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai - 400 001

Manager - Listing Listing Department **National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex Mumbai - 400 051

Ref: Script Code: 533259 and Symbol: SASTASUNDR

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update on the Buy-back proposal by Sastasundar Healthbuddy Limited, an unlisted material subsidiary of the Sastasundar Ventures Limited ("the Company")

Dear Sir/Madam,

This is in furtherance to the disclosure made by the Company on 19th September, 2025 and 30th September, 2025 regarding the Buyback proposal of Equity Shares made by Sastasundar Healthbuddy Limited ("SHBL"), unlisted material subsidiary of the Company.

Pursuant to the said Buy Back offer, we wish to inform you that SHBL has accepted 20,27,534 (Twenty Lakh Twenty-Seven Thousand Five Hundred and Thirty-Four only) equity shares tendered by Mitsubishi Corporation and SHBL shall pay the consideration not exceeding Rs. 1,00,00,00,044/-(Rupees One Hundred Crore and Forty-Four Only) within the statutory time line.

Further, the Company has not participated in the said Buy Back offer and consequently, the Company's shareholding in SHBL has increased from 72.14% to 78.89%.

The Company has received the aforesaid intimation from SHBL on November 11, 2025 at 3:59 PM.

The details as required in SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith as Annexure-I

The aforesaid information will also be available on the Company's website at www.sastasundarventures.com.

This is for your information and record.

Thanking you, Yours faithfully,

For Sastasundar Ventures Limited

Pratap Singh Company Secretary & Compliance Officer M.No. A24081

Encl: Disclosure made by the Company on 19th September, 2025 and 30th September, 2025

Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002

Annexure-I

Detail in terms of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc. as on March 31, 2025;	Name of the Target Entity: Sastasundar Healthbuddy Limited("SHBL") Authorised Capital: Rs. 33,10,00,000 Paid-up Capital: Rs. 23,70,35,240 Turnover: 1,08,498.21 Lacs
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No, as there is no transfer of resources, services or obligations between the Sastasundar Ventures Limited, holding Company and Sastasundar Healthbuddy Limited, material Subsidiary Company.
3.	Industry to which the entity being acquired belongs;	Business of wholesale trading of medicinal products, healthcare products and other Over the Counter (OTC) products.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Sastasundar Ventures Limited's shareholding in Sastasundar Healthbuddy Limited (SHBL) has increased pursuant to the buyback of shares held by Mitsubishi Corporation by SHBL.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	No approvals required
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Nature of Consideration - whether cash consideration or share swap or any other form and details of the same;	Not Applicable
8.	Cost of acquisition and/or the price at which the shares are acquired	Not Applicable
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Consequent to Buy Back of shares, the percentage of shareholding of Sastasundar Ventures Limited in Sastasundar Healthbuddy Limited will increase from 72.14% to 78.89%.

Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002

10. Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);

Brief Background: Sastasundar Healthbuddy Limited is engaged in business of wholesale trading of medicinal products, healthcare products and other Over the Counter (OTC) products.

Line of Business: Wholesale trading of pharmaceutical and medical goods

Date of incorporation: 04/03/2011

Turnover of last 3 years: FY 22-23: 1,02,623.76 Lacs FY 23-24: 1,35,172.85 Lacs FY 24-25: 1,08,498.21 Lacs

Country in which the acquired entity has presence: India



Azimgani House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002

Date: 30-09-2025

To

The General Manager

Department of Corporate Services

BSE Limited

Phiroze Jeejeebhoy Tower

Dalal Street, Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex

Mumbai - 400 051

Manager - Listing

Listing Department

Ref: Script Code: 533259 and Symbol: SASTASUNDR

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update on the Buy-back proposal by Sastasundar Healthbuddy Limited, unlisted material subsidiary of the Company

Dear Sir/Madam,

This is in furtherance of the disclosure made by the Company on 19th September, 2025 regarding the Buyback proposal of Equity Shares made by Sastasundar Healthbuddy Limited ("SHBL"), unlisted material subsidiary of the Company.

We hereby inform you that the shareholders of SHBL, in its Extra-Ordinary General Meeting held on 30th September, 2025 have approved the buy-back of not exceeding 20,27,534 (Twenty Lakh twenty seven thousand five hundred thirty four) fully paid-up equity shares (representing 8.55% of the total number of shares in the paid up equity share capital of SHBL) of Rs. 10/- (Ten) each, at a price of around Rs. 493.21/- (Rupees Four Hundred Ninety Three and twenty one paise) per share aggregating to a consideration not exceeding Rs. 1,00,00,00,044/- (Rupees One Hundred Crore and Forty Four Only).

The Company has received the aforesaid intimation from SHBL on 30th September, 2025 at 2:24 PM.

The aforesaid information will also be available on the Company's www.sastasundarventures.com.

This is for your information and record.

Thanking you, Yours faithfully,

For Sastasundar Ventures Limited

PRATAP SINGH

Pratap Singh Company Secretary & Compliance Officer M.No. A24081

Encl: Disclosure made by the Company on 19th September, 2025

Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002

Date: 19-09-2025

To

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower

Dalal Street, Mumbai - 400 001

Manager - Listing
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400 051

Ref: Script Code: 533259 and Symbol: SASTASUNDR

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 – Buy-back proposal by Sastasundar Healthbuddy Limited, material subsidiary Company of the Company

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations"), we hereby inform you that the Board of Directors of Sastasundar Healthbuddy Limited ("SHBL"), a material subsidiary of Sastasundar Ventures Limited ("the Company") at their Board Meeting held on 19th September, 2025 has approved buy-back of 20,27,534 (Twenty Lakh twenty seven thousand five hundred thirty four) fully paid-up equity shares of Rs. 10/- (Ten) each, at a price of Rs. 493.21/- (Rupees Four Hundred Ninety Three and twenty one paise only) per share aggregating to a consideration not exceeding Rs. 1,00,00,00,044/-, which is subject to approval of the shareholders of SHBL.

The Company has received the aforesaid intimation from SHBL on 19th September, 2025 at 3:16 PM.

Further, pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended) and trading restrictions placed by the Company's code of internal procedures and conduct for preventing Insider Trading; this is to inform you that the Trading Window for trading in the securities of the Company shall remain closed for all designated persons and their immediate relatives with immediate effect till Tuesday, September 23, 2025.

The aforesaid information will also be available on the Company's website at www.sastasundarventures.com.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sastasundar Ventures Limited

PRATAP SINGH Dogisal y signed by PIRATAP SINCH
DRI c. = RI, o PERDONAL
DRI c. = RI, o PERDONAL
2.5 4. 200-bc (1802 446.5 mid 46.11 mir bd 946.6 d 596.0 t),
2.5 4. 200-bc (1802 64.0 t) d 1.0 T 2.0 T 2

Pratap Singh

Company Secretary & Compliance Officer

M.No.: A24081